28 BioPharm International eBook February 2020 www.biopharminternational.com
Biopharma Contract Market Update
CMOs and CDMOs expanded their services and facilities in 2019 and
early 2020.
C
ontract manufacturing organizations
(CMOs) and contract development and
manufacturing organizations (CDMOs)
cont i nue to g row a nd e x pa nd to
keep up with the latest advances and
breakthroughs in services and technology for their
clients. The following are some notable acquisitions,
expansions, and industry partnerships that have
occurred in recent months.
ACQUISITION
Catalent continued its expansion into the cell and
gene t herapy development a nd ma nu fac t u r i ng
services sector with an announced acquisition of
MaSTherCell Global, Inc., a cell and gene therapy
CDMO with facilities in Europe and the United States
(1). The Feb. 3, 2020 announcement follows a May
2019 purchase of Paragon Bioservices for $1.2 billion
and the acquisition of development and manufactur-
ing facilities from Novamax in June 2019.
"MaSTherCell extends our leadership position in
the biotech industry, complements our leading gene
therapy offering, and allows us to deliver compre-
hensive development, manufacturing, analytical, fill/
finish, and clinical supply solutions for innovators
across the large-molecule space," said John Chiminski,
Catalent's chair and CEO, in the press statement.
NEW FACILITIES, EXPANSIONS, UPDATES
Catalent announced it completed the purchase of
Bristol-Myers Squibb's biologics, sterile, and oral
solid dose product manufacturing and packaging
A
Stockphoto
-
Stock.adobe.com
THE EDITORS OF BIOPHARM INTERNATIONAL
Outsourcing Resources Operations